MARKET

SCYX

SCYX

Scynexis
NASDAQ
3.850
+0.040
+1.05%
After Hours: 3.920 +0.07 +1.82% 19:42 06/26 EDT
OPEN
3.760
PREV CLOSE
3.810
HIGH
3.970
LOW
3.695
VOLUME
49.11K
TURNOVER
--
52 WEEK HIGH
10.48
52 WEEK LOW
3.680
MARKET CAP
38.23M
P/E (TTM)
-0.9892
1D
5D
1M
3M
1Y
5Y
1D
SCYNEXIS Shareholders Approve Governance and Equity Plan Changes
TipRanks · 1d ago
SCYNEXIS boosts authorized shares to 65,000,000 from 23,750,000
PUBT · 1d ago
Weekly Report: what happened at SCYX last week (0615-0619)?
Weekly Report · 5d ago
Weekly Report: what happened at SCYX last week (0608-0612)?
Weekly Report · 06/15 10:19
Weekly Report: what happened at SCYX last week (0601-0605)?
Weekly Report · 06/08 10:15
Weekly Report: what happened at SCYX last week (0525-0529)?
Weekly Report · 06/01 10:19
Upcoming Stock Splits This Week (June 1 to June 5) – Stay Invested
TipRanks · 05/31 13:45
NASDAQ TRADE HALT <SCYX.O> HALT NEWS PENDING AT 03:28 AM
Reuters · 05/30 07:28
More
About SCYX
SCYNEXIS, Inc. is a biotechnology company focused on developing therapies to address severe rare diseases. The Company's SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. Its proprietary antifungal platform, fungerps, includes BREXAFEMME (ibrexafungerp tablets), which has been licensed to GSK, and SCY-247, which is in clinical stages of development. Its SCY-770 is a novel, highly selective, direct AMP-activated protein kinase (AMPK) activator for the treatment of ADPKD, a genetic cause of end-stage renal failure. Its SCY-770 is designed to address many of the underlying drivers of ADPKD by reducing cyst growth and disease progression. The United States Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC).

Webull offers SCYNEXIS Inc stock information, including NASDAQ: SCYX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SCYX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SCYX stock methods without spending real money on the virtual paper trading platform.